Arvinas, Inc
XNAS:ARVN
12.59
$60.00 - 200.00
$12.30 - 20.00
$12.3
$12.59
$12.47
$12.42
27
5.9
629669
3428706.3
55285112.36
Chart
TendieTensor AI Analysis
Company
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.
Fundamentals
430
-15.670000
1.578700
-0.48
100
BBG00LW7YK82
BBG00LW7YL08
73.42M
70.82M
Technicals
Short Interest
—
—
—
Higher = harder to cover
—
Prev: —
—
—
5D avg: —
—
Discussion
Login to participate in discussions.
Recent News
Related Stocks
Based on the portfolios of people who own ARVN. This is a list generated by trading data from 3rd party trading platforms, and it's not a recommendation.